CHANGCHUN HIGH-TECH

In June 1993, CHANGCHUN HIGH-TECH INDUSTRIES(GROUP)Inc. was exclusively established by Changchun High-tech Industrial Development Corporation with a total share capital of 137.5 million shares. On December 18, 1996, the company's stock was listed on the Shenzhen Stock Exchange, making it one of the earliest batch of listed companies in Northeast China. Over the more than 20 years since its listing, CHANGCHUN HIGH-TECH has successfully transformed from its initial focus on infrastructure construction in high-tech zones to become an enterprise group dedicated to pharmaceutical science and technology innovation and industrial investment. The company consistently upholds the corporate culture of "innovation, focus, inclusiveness, sharing, and development," practicing core values that create value for customers, opportunities for employees, benefits for shareholders, and assume social responsibilities. It has clearly positioned itself in the biopharmaceutical industry as its main focus, supplemented by real estate, forming three major industrial development platforms: genetic engineering drugs, biological vaccines, and modern Chinese medicine. This has led to a strong development pattern driven by four key subsidiaries—Jin Sai Pharmaceutical, Baike Biotech, Hua Kang Pharmaceutical, and Hi-Tech Real Estate—creating a favorable situation of shared development and win-win cooperation. The company’s operating performance has continued to grow, ranking 73rd and 56th respectively in the national pharmaceutical industry top 100 rankings in 2017 and 2018.